Third round of improvements to blood thinner standard announced by USP

RARITAN, N.J., May 2, 2012 /PRNewswire/ -- Janssen Research & Development, LLC, (Janssen), announced today that it has submitted supplemental New Drug Applications (sNDAs) to the U.S.

A novel oral anti-coagulant outperformed the injected standard therapy on important safety measures for initial and long-term treatment of pulmonary embolism – a blockage of lung blood vessels usually caused by a clot – and showed comparable efficacy.

A novel oral anti-coagulant outperformed the injected standard therapy on important safety measures for initial and long-term treatment of pulmonary embolism – a blockage of lung blood vessels usually caused by a clot – and showed comparable efficacy.

CHICAGO, March 26, 2012 /PRNewswire/ -- Janssen Research & Development, LLC, (Janssen), announced results of the EINSTEIN-PE study showing that the oral anticoagulant XARELTO(®) (rivaroxaban)